| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Desoxyrhaponticin may target various signaling pathways involved in inflammation and cancer, including NF-κB, MAPK, and PI3K/Akt pathways. It may also interact with estrogen receptors due to its structural similarity to resveratrol. It is a phytoalexin and may have antimicrobial and antifungal activities.
|
|---|---|
| ln Vitro |
In vitro, desoxyrhaponticin has been shown to inhibit cancer cell proliferation and induce apoptosis in various cancer cell lines. It may also have antioxidant activity by scavenging free radicals and reducing oxidative stress. It can modulate inflammatory cytokine production and inhibit the expression of COX-2 and iNOS.
|
| ln Vivo |
In vivo, desoxyrhaponticin has been studied in animal models of inflammation and cancer. It may have anti-inflammatory effects in models of colitis and arthritis. It may also have chemopreventive effects in models of carcinogenesis. Its bioavailability and metabolism are areas of active research.
|
| Enzyme Assay |
For non-cellular enzyme assays, desoxyrhaponticin can be tested for antioxidant activity using DPPH, ABTS, or FRAP assays. It can also be tested for inhibition of enzymes such as COX-2, iNOS, and MMPs using standard enzyme activity assays.
|
| Cell Assay |
For in vitro cell-based assays, cancer cell lines and inflammatory cell models are cultured and treated with desoxyrhaponticin. Cell proliferation, apoptosis, and inflammatory marker expression are assessed using MTT assays, flow cytometry, ELISA, and Western blotting.
|
| Animal Protocol |
For in vivo animal studies, desoxyrhaponticin can be administered orally or intraperitoneally to animal models of disease. Inflammation models (such as DSS-induced colitis or carrageenan-induced paw edema) and cancer models (such as xenograft or chemically-induced carcinogenesis) can be used. Inflammatory markers and tumor growth are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties include solubility in DMSO and ethanol. It is a glycoside and may be hydrolyzed to the aglycone in the intestine. Bioavailability may be limited due to poor absorption and extensive metabolism. Storage is typically at -20°C. It is a solid and should be handled with standard laboratory precautions.
|
| Toxicity/Toxicokinetics |
Toxicological data for desoxyrhaponticin is limited. As a natural product, it is generally considered safe at low doses. No significant toxicity has been reported in preclinical studies.
|
| References | |
| Additional Infomation |
Desoxyrhaponticin is a stilbene compound and glycoside. It has been reported to be found in Veratrum dauricum, Rheum palmatum, and other organisms with relevant data.
Desoxyrhaponticin is a naturally occurring stilbenoid glycoside found in rhubarb. It has antioxidant, anti-inflammatory, and anti-cancer activities. It is a phytoalexin and may have antimicrobial effects. It is a derivative of rhaponticin and is structurally similar to resveratrol. |
| Molecular Formula |
C21H24O8
|
|---|---|
| Molecular Weight |
404.4105
|
| Exact Mass |
404.147
|
| CAS # |
30197-14-9
|
| PubChem CID |
5316606
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
700.5±60.0 °C at 760 mmHg
|
| Flash Point |
377.5±32.9 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.691
|
| LogP |
1.48
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
29
|
| Complexity |
521
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
COC1=CC=C(C=C1)/C=C/C2=CC(=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O
|
| InChi Key |
MFMQRDLLSRLUJY-DXKBKAGUSA-N
|
| InChi Code |
InChI=1S/C21H24O8/c1-27-15-6-4-12(5-7-15)2-3-13-8-14(23)10-16(9-13)28-21-20(26)19(25)18(24)17(11-22)29-21/h2-10,17-26H,11H2,1H3/b3-2+/t17-,18-,19+,20-,21-/m1/s1
|
| Chemical Name |
(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-methoxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~247.27 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.18 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4727 mL | 12.3637 mL | 24.7274 mL | |
| 5 mM | 0.4945 mL | 2.4727 mL | 4.9455 mL | |
| 10 mM | 0.2473 mL | 1.2364 mL | 2.4727 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
